A new drug delivery method using nano-sized molecules to carry the chemotherapy drug doxorubicin to tumors improves the effectiveness of the drug in mice and increases their survival time, according to a study published online June 26 in the Journal of the National Cancer Institute.
In the past, similar drug carriers have improved targeted delivery of the drugs and reduced toxicity, but they sometimes decreased the drugs’ ability to kill the tumor cells. Using a new drug carrier, Ning Tang of the Chinese Academy of Sciences in Beijing and colleagues compared tumor growth and survival in mice that were given doxorubicin in the nanocarriers or on its own.
Doxorubicin delivered by nanocarriers was more effective in preventing tumor growth than free doxorubicin, and the mice receiving this treatment method lived longer and had fewer toxic side effects.
“Encapsulation of doxorubicin…increased its accumulation and penetration in tumors in terms of both the percentage of cells that were reached by the drug and the intracellular levels that were attained,” the authors write.
In an accompanying editorial, Matthew Dreher, Ph.D., of the National Institutes of Health in Bethesda, Md., and Ashutosh Chilkoti, Ph.D., of Duke University in Durham, N.C., discuss the future of drug delivery, which they think should focus on three important research areas—drug combinations, targeting, and integration.
“The study by Tang [and colleagues] is a simple but effective demonstration of the benefits of integration of a drug with an appropriate carrier to yield a striking gain in efficacy,” the authors write. “May the days of pharmacological missiles that miss their target and friendly fire that kills patients soon be over!”
Note to Reporters:
We may be starting up an e-mail list to alert reporters when papers are available on the EurekAlert site. If you would be interested on being on this list, please let us know at firstname.lastname@example.org. The content will continue to be available through EurekAlert’s e-mail system and our EurekAlert page.
The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jnci.oxfordjournals.org/.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.